EXHIBIT G

| | Plaintiff | fs' Preliminary Li | st of Custodians | for ZHP and It | s Subsidiaries | as of 11/25/2019 |
|------------|-----------|--|---------------------------------------|------------------------|----------------|---|
| First name | Last name | Title | Department | Co. | Proffered by | Explanation |
| | | | Senior N | Ianagement | _ | |
| Īva. | Du | Vice President of ZHP, CEO of Huahai US, Prinston, Solco, and PrinJohnson | | See Title Cell | P - 10.8.19 | PrinJohnson's Facebook Identifies |
| Jun | Du | PrinJohnson | | See Title Cell | P - 10.8.19 | Du as its CEO |
| Baohua | Chen | Chairman and General Manager | | ZHP and PrinJohnson | P - 11.12.19 | His senior role in the investigation of the Valsartan contamination. PrinJohnson's Facebook identifies him as its CEO. |
| | | | | alytical | | |
| Xie | Chaojun | | Analyst | ZHP | P - 10.8.19 | |
| Min | Li | VP | Analytical Operations | ZHP | D - 9.23.19 | |
| Minfa | Wang | VP | Analytical Operations | ZHP/Prinston | P - 10.8.19 | |
| Qing | Wang | * 1 | орегинона | ZHP | P - 10.8.19 | |
| Dachuan | Zhao | VP | Analytical, Shanghai R&D Center | ZHP | P - 11.12.19 | Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158 |
| Xin | Geng | Post Doctoral Fellow and Research Scientist | | Hauahai US | P - 11.12.19 | "Expertise in various purification techniques including chromatography, recrystallization, and distillation" -Linkedin |
| Jack | Guan | Senior Director Analytical Operations | Channe | Prinston | P - 11.12.19 | "A pharmaceutical professional with strong expertise in analytical R&D, Quality Control, Preformulation, Quality Assurance, Compliance and Regulatory Affairs. Proven track records of leading operations and activities in analytical R&D, quality units, health authority inspections, and project management." -Linkedin |
| | | Analytical and Testing Department | Branch Analytical | | | |
| XiaXia | Zhang | Manager Finished Dose Gase Stage | Center Chuannan Branch Analytical | ZHP | P - 11.22.19 | Org Chart |
| Jun | Wang | Team | Center | ZHP | P - 11.22.19 | Org Chart |
| v vrži | , and | Finished Dose Liquid Phase | Chuannan Branch Analytical | | 11.22.17 | |
| Chun | Yang | Team | Center | ZHP | P - 11.22.19 | Org Chart |

| | | D M . 1 1 | 1 | | | |
|-----------|---------|----------------|----------------------|------------|--------------|--|
| | | Raw Material | CI | | | |
| | | Central | Chuannan | | | |
| | | Control | Branch | | | |
| | | Instrument | Analytical | | | |
| Guang | Zheng | Team | Center | ZHP | P - 11.22.19 | Org Chart |
| | | Raw Material | | | | |
| | | Central | | | | |
| | | Control | Chuannan | | | |
| | | Physico- | Branch | | | |
| | | Chemical | Analytical | | | |
| XianLiang | Zhang | Team | Center | ZHP | P - 11.22.19 | Org Chart |
| | | | Chuannan | | | |
| | | | Branch | | | |
| | | | Analytical | | | |
| Yun | Jin | | Center | ZHP | P - 11.22.19 | Org Chart |
| | | | | uality | | |
| *** | C1 | T I D | API Quality | ZIID | D 10010 | |
| Wei | Cheng | VP | Assurance | ZHP | P - 10.8.19 | |
| | | | Quality | | | |
| Remonda | Gergis | VP | Assurance | Prinston | P - 10.8.19 | |
| 71 | | Deputy | Quality | | D 10010 | |
| Zheng | Youqing | Manager | Assurance | ZHP | P - 10.8.19 | |
| | | | Quality | | | |
| | | | Assurance (API | | | |
| Jucai | Ge | Director | Division) | ZHP | D - 9.23.19 | |
| | | | Quality | | | |
| ** 1. | | Assistant | Assurance (API | | D 10 7 10 | |
| Yuelin | Hu | Director | Division) | ZHP | D - 10.7.19 | |
| | | Independent | | ZHP and | | |
| Ziqiang | Gu | Consultant | | Prinston | P - 10.8.19 | |
| Ziqiang | Gu | Consultant | Quality | FIIIISTOII | r - 10.6.19 | |
| | | | Assurance | | | |
| Vischong | Zhao | Director | (Chuannan Site) | ZHP | P - 10.8.19 | |
| Xiaohong | ZHaO | Director | (Citualillali Site) | LIIF | F - 10.8.19 | Prepared Method Validation |
| | | | | | | Report of Valsartan |
| Hongliang | Wang | | Quality | ZHP | P - 11.12.19 | PRINSTON00031401 |
| Trongnang | vv ang | | Quality | 2111 | 1 - 11.12.19 | Reviewed part of Method |
| | | | | | | Validation Report of Valsartan |
| Zhen | Ye | | Quality | ZHP | P - 11.12.19 | PRINSTON00031402 |
| ZHEH | 1 0 | | • | ΖПΓ | r - 11.12.19 | Attended close out meeting on |
| | | | Corporate | | | |
| Doorbon | Chan | Director | Quality | 7UD | D 11 12 10 | 5.19.17 regarding FDA inspection PRINSTON0074158 |
| Baozhen | Chen | Director | Assurance | ZHP | P - 11.12.19 | |
| | | | Quality | | | Attended close out meeting on |
| Cunvice | Ye | Vice President | Assurance, | 7UD | D 11 12 10 | 5.19.17 regarding FDA inspection PRINSTON0074158 |
| Cunxiao | re | Vice President | neauquarters | ZHP | P - 11.12.19 | FKIN51UN00/4138 |
| | | | | | | Prepared Deviation Investigation |
| | | | | | | Report of Valsartan TEA Process |
| | | | Quality | | | V1, 2, & 3 PRINSTON0073443, |
| Caifeng | 7hac | Managar | Quality Assurance | ZHP | P - 11.12.19 | 0075797, 0076100 |
| Canteng | Zhao | Manager | Assurance | LΠΓ | r - 11.12.19 | 00/3/9/, 00/0100 |

| | | Assistant | Quality Assurance at Chuannan Site | | | Reviewed and signed off on Deviation Investigation Report of Valsartan TEA Process V1, 2, & 3 PRINSTON0073443, 0075797, 0076100; attended 5.19.17 meeting after the FDA inspection |
|---------------|-------------|-------------------------|---|------------|---|--|
| Dongqin | Wang | Director | East Zone | ZHP | P - 11.12.19 | PRINSTON0074159 |
| Zhizhang | Ding | Assistant Manager | Formulation Quality Assurance | ZHP | P - 11.12.19 | Reviewed and approved Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384 |
| VE | al. | Senior | API Quality | | D. 11.12.10 | Reviewed and approved Validation Report of LC-MS Method for NDBA in Losartan Potassium PRINSTON0074642; ; reviewed and approved the Validation Report of LC-MS Method for NMBA in Irbesartan |
| Y.F. Xiong | Chen Fei | Supervisor Analyst | Assurance Quality Control | ZHP ZHP | P - 11.12.19 P - 10.8.19 | PRINSTON0074712 |
| Hu | Guangping | Director | Quality Control | ZHP | P - 10.8.19 | |
| Huang | Rui | Director | Quality Control | ZHP | P - 10.8.19 | |
| Minli | Zhang | Director | Finished Dose Quality Assurance and Quality Control Quality Control | ZHP | D - 10.16.19 | |
| Qiangming | Li | Director | (API Division) | ZHP | D - 9.23.19 | |
| Zie | Chaojun | Analyst | Quality Control | ZHP | P - 10.8.19 | |
| Quang | Zhou | Analyst | Quality Research | ZHP | D - 10.23.19 | |
| Vina | Xiong | Supervisor | Quality Research | ZUD | D - 10.23.19 | |
| Ying | Along | Associate | Quanty Research | ZH | Discussed but not agreed to | |
| Fong E. | Zhuong | Manager | Quality Research | ZHP | on 10.23.19 | Org Chart |
| | | Technical Assistant | - | | Discussed but not agreed to | |
| Dan Ping | Cai | Director | Quality Research | ZHP | on 10.23.19 | Org Chart |
| Vijanyan | Chen | Supervisor | Quality Research | 7НР | Discussed but not agreed to on 10.23.19 | Org Chart |
| Yuanyan | | Assistant Director/Mana | | | | Reviewed and signed off on Deviation Investigation Reports of Valsartan TEA Process PRINSTON0073443, etc.; attended close out meeting on 5.19.17 regarding FDA inspection |
| Yinhua | Tang | ger | Quality Control | ZHP | P - 11.12.19 | PRINSTON0074158 |
| Fei | Shang | QP | Quality VP | ZHP | P - 11.12.19 | Reviewed and approved the third version of the Deviation Investigation into the TEA process PRINSTON0076100 |

| Yun | Jin | Supervisor | Chuannan Quality Control | ZHP | P - 11.12.19 | Drafted Assay Method Validation Report for Valsartan (Supplement) PRINSTON00009948; draft Chiral Purity Analytical Method Validation Protocol for TDCI Compound PRINSTON00077405 |
|----------|-------|--------------------|--------------------------------|-----|--------------|---|
| Tian | Zhang | Analyst | Chuannan Q Control | ZHP | P - 11.12.19 | Reviewed and signed off on Assay Method Validation Report for Valsartan (Supplement) PRINSTON00009948; reviewed and signed off on Chiral Purity Analytical Method Validation Protocal for TDCI Compound PRINSTON00077405 |
| Xianhua | Zhang | Deputy Director | Chuannan Quality Control | ZHP | P - 11.12.19 | Reviewed and signed off on Assay Method Validation Report for Valsartan (Supplement) PRINSTON00009948; reviewed and signed off on Chiral Purity Analytical Method Validation Protocal for TDCI Compound PRINSTON00077405 |
| Yuping | Chen | Deputy Manager | Formulation Quality Control | ZHP | P - 11.12.19 | Author of Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384 |
| Xiaoling | Li | Manager | Formulation Quality Control | ZHP | P - 11.12.19 | Reviewed and signed off on Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384 |
| Qiang | Zhuo | Analyst | API Quality Research | ZHP | P - 11.12.19 | Drafted Validation Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326 |
| Tong | Wu | Analyst | API Quality Research | ZHP | P - 11.12.19 | Drafted Validation Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326 |

| Tan | Xiao | Senior Supervisor | API Quality Research | ZHP | P - 11.12.19 | Drafted Validation Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326; reviewed and approved Validation report of the LC-MS method for NDBA in Losartan Potassium PRINSTON0074642; reviewed and approved the Validation Report of LC-MS Method for NMBA in Irbesartan PRINSTON0074712 |
|----------------|--------------|-----------------------|---------------------------|------------|------------------------------|---|
| Wenbin | Chen | Analysis Director | API Quality Research | ZHP | P - 11.12.19 | Reviewed and signed off on Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326; ; reviewed and approved the Validation Report of LC-MS Method for NMBA in Irbesartan PRINSTON0074712 |
| Nan | Tong | Senior Supervisor | API Quality Research | ZHP | P - 11.12.19 | Approved the cGMP compliance for its intended use of Report of GC-MS Method for Detection of NDMA in Valsartan and Hydrochlorothiazide Tablets PRINSTON00000326 |
| Wenping | Hu | Team Leader | Quality Research | ZHP | P - 11.12.19 | Reviewed data in Hydrochlorothiazide Residual Solvent Method Validation Report PRINSTON00064288; Reviewed Comparison of Valsartan USP Method and In-house Method for Integrity and Correctness PRINSTON00064389 |
| Wenquan | Zhu | Director | API Quality Research | ZHP | D- 10.16.19 | |
| X. G. | Liu | Quality Researcher | API Quality Research | ZHP | P - 11.12.19 | Drafted Validation report of the LC-MS method for NDBA in Losartan Potassium PRINSTON0074642 |
| Y.Y. | Не | Quality Researcher | API Quality Research | ZHP | P - 11.12.19 | Drafted Validation Report of LC- MS Method for NMBA in Irbesartan PRINSTON0074712 Approved the Deviation Investigation Reports of Valsartan |
| Ye | Jenson | | QP | ZHP | P - 11.12.19 | TEA Process PRINSTON0073443, etc. |
| Τ' | 117 | D | Quality | 7115 | D 11 00 10 | DD D ICTO MODOGEOGO |
| Jieyun Ting | Wang Sung | Director | Assurance Quality Control | ZHP ZHP | P - 11.22.19 P - 11.22.19 | PRINSTON00077850 Org Chart |
| ring | Sung | Manager | Quality Control | LIL | r - 11.22.19 | Org Chart |

| | | Deputy | | | | |
|------------|-------|-------------------|-------------------|-----------|--------------|-----------------------------------|
| | | Manager, | | | | |
| Jian | Ye | Group I | Quality Control | ZHP | P - 11.22.19 | Org Chart |
| | | General | | | | |
| | | Detection, | | | | |
| | | Tachnical | API Quality | | | |
| | | Deputy | Study/Research | | | |
| Houming | Zhou | Director | Department | ZHP | P - 11.22.19 | Org Chart |
| | | | API Quality | | | |
| | | Associate | Study/Research | | | |
| Xiao | Yu | Director | Department | ZHP | P - 11.22.19 | Org Chart |
| | | | * | | | |
| Yang | Han | Supervisor | Quality Research | ZHP | P - 11.22.19 | Org Chart |
| | | | | | | Prepared Comparison of Valsartan |
| | | | | | | USP Method and In-house Method |
| Chaohua | Bao | Supervisor | API QR | ZHP | P - 11.22.19 | PRINSTON00064389 |
| | 12.00 | Super (Issue | | facturing | 1 11122119 | 1111.5151.0000.009 |
| | | | Technical for | | | |
| Xiamong | Liu | Head | Finished Dose | ZHP | D - 10.16.19 | |
| | | Valsartan | | | | Identified as the person |
| | | Workshop | | | | "responsible for production of |
| Congsheng | Jin | Director | | ZHP | P - 11.12.19 | Valsartan" |
| | | | | | | |
| | | | | | | Described as a "professional |
| | | | | | | engineer," and "has a wide |
| | | | | | | experience at production |
| | | Factor | | | | technology management and is |
| | | Assistant | | | | responsible for the technological |
| Yongjun | Jin | Director | Manufacturing | ZHP | P - 11.12.19 | development of all bulk drugs" |
| Toligjuli | 3111 | Director | Technical | ZIII | 1 - 11.12.17 | development of all bulk drugs |
| Dong | Peng | Director | Department | ZHP | D - 9.23.19 | |
| Dollg | 1 chg | Senior | API | Z111 | D - 9.23.19 | |
| Peng | Wang | Director | Manufacturing | ZHP | D - 9.23.19 | |
| 1 clig | wang | Technology | Manufacturing | Z111 | D - 9.23.19 | |
| Youhu | Wang | Leader | | ZHP | P - 11.12.19 | "Is responsible for Valsartan" |
| Toulia | wung | Leader | | 2.111 | 1 11.12.17 | is responsible for valuation |
| | | API and | | | | |
| | | Intermediate | | | | Responsible for all bulk drugs |
| Jiangzhong | Yu | | Manufacturing | ZHP | P - 11.12.19 | (including intermediates) at ZHP |
| rangenong | | T talle tylanager | Technical, API | | 1 11.12.17 | (merading intermediates) at 2111 |
| | | | Chuannan site | | | |
| | | | West Zone | | | Attended close out meeting on |
| | | Director | (counterpart to | | | 5.19.17 regarding FDA inspection |
| Wenling | Zhang | Assistant | Peng Dong) | ZHP | P - 11.12.19 | PRINSTON0074158 |
| | | | API | | | |
| | | | Operation/Facilit | | | Attended close out meeting on |
| | | | y Director, API | | | 5.19.17 regarding FDA inspection |
| Lijin | Jiang | VP | Chuannan Site | ZHP | P - 11.12.19 | PRINSTON0074158 |
| J | 5 | | Engineering and | | | .==== |
| | | | Maintenance, | | | Attended close out meeting on |
| | | Deputy Plant | | | | 5.19.17 regarding FDA inspection |
| Zhengjun | Jia | Director | site East Zone | ZHP | P - 11.12.19 | PRINSTON0074158 |
| <u>. u</u> | | i | 1 | i | | |

| | 1 | Т | · | | | 1 |
|----------------|------------|-----------------------------------|---|--------------------------------------|--------------|--|
| Junhui | Zuo | | | | P - 11.12.19 | Attended close out meeting on 5.19.17 regarding FDA inspection PRINSTON0074158 |
| Wei | Chen | Deputy Director | Production Department | ZHP | P - 11.12.19 | Reviewed and approved Deviation Investigation Reports regarding the TEA Process PRINSTON0073443, 0075797, 0076100 |
| Lina | Wu | Senior Supervisor | Formulation Technology at ZHP | ZHP | P - 11.12.19 | Author of Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384 |
| Xiaoming | Liu | Director | Formulation Technology at ZHP | ZHP | P - 11.12.19 | Reviewed and signed off on Elemental Impurity Risk Assessment Report for Valsartan Tablets PRINSTON00036384 |
| Eric Wen-Chien | Tsai, PhD | General Manager | | Prinston and Prinbury BioPharm | P - 11.12.19 | Authorized signatory and sponsor or Quality Assurance Authentification of Valsartan. PRINSTON00029811. "Eric joined Prinbury BioPharm as General Manager in 2009, wholly owned subsidiary of Prinston, a Research and Development center located in Shanghai China. In this role he leads the R&D efforts has been making significant contribution to Prinston pipeline growth. Eric came to the company with strong technical expertise and management skills." -Prinston Website |
| Pieter | Groenewoud | Executive Director | Technology | ZHP | P - 11.12.19 | Reviewed Master Packaging Record Approval PRINSTON00021688 |
| | | | | | | |
| Chunmin | Xu | Vice President | | ZHP | P - 11.22.19 | PRINSTON00070584, 79392 |
| Hu | Zhou | Factory Director Factory | | ZHP | P - 11.22.19 | PRINSTON00070586 |
| D., | 71 | Assistant | | 7110 | D 11 22 12 | DDINICTONIO0070507 F0005 |
| Ruqi | Zhou | Director Technical | | ZHP | P - 11.22.19 | PRINSTON00070587, 79392 |
| Kaai | Yang | Manager | | ZHP | P - 11.22.19 | PRINSTON00070587, 79392 |
| Ruping | Ren | Auxiliary Workshop Director | | ZHP | P - 11.22.19 | PRINSTON00077851 |
| Meng | Yanhua | General Manager | Chuannan Product Technical Center | | P - 11.22.19 | Org Chart |
| | ! | + | L | l | <u> </u> | + ~ |

| | _ | | 1 | 1 | 1 | |
|-------------------|----------|---------------------------------|---|--|---|--|
| Yan | Fengfeng | Director of Tech | Chuannan Product Technical Center | ZHP | P - 11.22.19 | Org Chart |
| Liang | Zunjun | Associate Director | Chuannan Product Technical Center | ZHP | P - 11.22.19 | Org Chart |
| Hu | Zhichen | Manager | Chuannan Product Technical Center | ZHP | P - 11.22.19 | Org Chart |
| | | Manager | Chuannan Product | | 111.22.19 | |
| Zhan | Xiauhui | "(Valsartan)" | Technical Center | ZHP | P - 11.22.19 | Org Chart |
| | | General Supporting | Chuannan Product | | D 11 22 10 | |
| Xie | Mengmeng | Group | Technical Center | <u> </u> | P - 11.22.19 | Org Chart |
| | | | Regulatory | ulatory | 1 | |
| Linhong | | | Affairs | | | |
| (Linda) | Lin | Director | Department | ZHP | D - 9.23.19 | |
| Wei | Chen | Translator | | ZHP | P - 11.12.19 | Translatered 08/26/2018 Ltr to the FDA |
| Zhi | Chen | | | Huahai US | P - 10.8.19 | |
| Yanfeng (Lucy) | Liu | Deputy Director / Manager | Regulatory Affairs | ZHP | D - 10.7.19 | |
| (Lucy) | | | Head of Regulatory | | D - 10.7.19 | |
| Lije | Wang | VP | Affairs | Prinston | P - 10.8.19 | |
| Ying | Xiong | Supervisor Senior | Regulatory Affairs Regulatory | ZHP | D 10.16.19 | |
| Quo (Kathy) | Zhang | Manager | Affairs | Huahai US Huahai US | P – 10.8.19 | |
| | | | | (linkedin), Prinston (website), and Solco (affidavits of | P for Prinston/Huah ai US - 10.8.19 / Solco - | He has accepted service as Solco's |
| Xiaodi | Guo | Vice President | | service) | 11.12.19 | VP. |
| Wei (Helen) | Tong | Director | Regulatory Affairs | ZHP and Prinston? | P - 11.12.19 | Listed on ANDA Documents |
| Ting (Ada) | Zhou | Assistant Director | Regulatory Affairs | ZHP | D - 10.7.19 | |
| Louis | Zhao | | Regulatory Affairs | Prinston | P - 11.12.19 | Linkedin |

| Guangyu | Luo | Associate (2013-2015), Senior Associate (2015-2016), Specialist (2016-2017), Manager (2017-Present) Senior Associate | Regulatory Affairs | Prinston Prinston | P - 11.12.19 P - 11.12.19 | "Regulatory Affairs, mainly on regulatory submissions (from draft to e-CTD compilation), pharmacovigilance (AE handling and submission) and generic labeling (content, artwork and SPL)." -Linkedin |
|--------------|----------|--|---------------------------------------|-------------------|---------------------------|---|
| Jenny | Lu | Associate | Finished Dose | Tilliston | 1 - 11.12.19 | Elikediii |
| Variation or | 71 | Dinastan | | 7110 | D 10 22 10 | |
| Yuding | Zhao | Director | RA | ZHP | D - 10.23.19 | G P G . GMDI II G |
| Yiming | Tang | | | | P - 11.22.19 | Contact Person for ZHP's U.S. Agent PRINSTON0076915 |
| Tilling | Tung | | API R&D, | | 1 11.22.19 | rigent i tarts i ortou / u / i s |
| | | | Regulation | | | |
| C | D | M | | ZIID | D 11 22 10 | One Chart |
| Sun | Dengxue | Manager | Affairs | ZHP | P - 11.22.19 | Org Chart |
| Lin | Jie | Deputy Manager | API Patent, Regulation Affairs | ZHP | P - 11.22.19 | Org Chart |
| | | | Pro | curement | | |
| Min | Hu | | Purchasing | ZHP | D -10.16.19 | |
| Weiwei | Xu | | Purchasing | ZHP | D - 10.16.19 | |
| Min | Xu | | Purchasing | ZHP | D -10.16.19 | |
| Min | Xang | | Procurement | ZHP | D - 10.16.19 | |
| Zheng | Gaozhe | | Purchasing | ZHP | D - 10.16.19 | Was a person who was responsible for procuring solvents |
| | | | | PI Sales | | 1 8 |
| Minda | Cai | Former VP | API Sales | ZHP | D - 10.16.19 | |
| | | | Business | | | |
| Jie | Wang | VP | Development | ZHP | D - 9.23.19 | |
| G1 | | D : | Business | 77170 | D 101610 | |
| Sheng | Zhong | Director | Development | ZHP | D - 10.16.19 | |
| Wei | Chang | Translator | Business Development, API Sales | ZHP | D - 10.23.19 | |
| Hongchao | Li | Manager | Business Development | ZHP | D - 10.16.19 | |
| | | | Business Development, | | | |
| Xu | Mi | | API Sales | ZHP | D - 10.16.19 | |
| Wang | Yihua | Vice President | Sales | ZHP | P - 11.22.19 | Org Chart |
| Ki | Qing | Customer" | Sales | ZHP | P - 11.22.19 | Org Chart |
| Tong | Zengyuan | "Customer Service" Manager | Sales | ZHP | P - 11.22.19 | Org Chart |
| Tang | Fengyang | Assistant | Sales | ZHP | P - 11.25.19 | Org Chart |
| Wang | Lina | Manager Assistant | Sales | ZHP | P - 11.25.19 | Org Chart |
| | | | | | | |

| | | Director of | | | | |
|-------------|----------|-----------------|-------|----------------|---------------|-----------------------------------|
| | | Original Drug, | | | | |
| | | Key Account | | | | |
| | | Business | | | | |
| Li | Qing | Department | Sales | ZHP | P - 11.25.19 | Org Chart |
| | | Director | | | | |
| Xu | Baoxi | Assistant | Sales | ZHP | P - 11.25.19 | Org Chart |
| | | Manager of | | | | |
| | | Document | | | | |
| Wu | Yuehua | Group | Sales | ZHP | P - 11.25.19 | Org Chart |
| | | Assistant | | | | |
| | | Manager of | | | | |
| | | Office Work | | | | |
| Wang | Haiqun | Group | Sales | ZHP | P - 11.25.19 | Org Chart |
| wang | Traiquii | Отопр | Baics | Other Sales | 1 - 11.23.17 | Org Chart |
| John | Iozzia | Director | Sales | Huahai US | D - 10.16.19 | |
| | | | | | D - 10.22.19 | |
| | | | | Solco/Prinston | for Solco / | |
| | | | | at some point | Prinston - | |
| Chris | Keith | Director | Sales | as VP | 11.12.19 | Solco's Website |
| | | | | | | |
| | | SVP, Business | | | | |
| | | Development | | | | |
| Lesley | Zhu | & Portfolio | Sales | Prinston | P - 10.8.19 | |
| | | | | Huahai US | | |
| | | | | (linkedin), | | |
| | | | | Prinston | | |
| | | | | (website), & | | |
| | | | | Solco | | |
| | | VP, President, | | (website), | P for Solco - | |
| Hai | Wang | President | | respectively | 10.8.19 | |
| 1141 | wang | Manager of | | respectively | 10.6.17 | |
| | | Business | | Huahai US | | |
| | | Development | | (2007-2012) | | |
| | | and Senior | | and Prinston | | |
| | | Director of | | (2012- | | |
| | | | | ` | | |
| Min | Hu | Business | | Present), | P - 11.12.19 | Linkedin |
| IVIIII | пи | Development | | respectively | F - 11.12.19 | Linkedin |
| David | Ayres | Vice President | Sales | Solco | P - 11.12.19 | Solco's Website |
| Davia | rijies | vice i resident | Sures | 50100 | 1 11.12.19 | Select Weekle |
| | | Scientist (2012 | | | | |
| | | 2016), | | | | "Working at formulation position |
| | | Manager | 1 | | | of Product Development |
| Xin (Will) | Не | (2019-Present) | | Prinston | P - 11.12.19 | Department." -Linkedin |
| (| | Senior | | 111101011 | -1112117 | F |
| | | Associate of | | | | |
| | | Business | 1 | | | |
| | | Development/ | | | | |
| Peng | Shang | Supply Chain | | Prinston | P - 11.12.19 | Linkedin |
| 1 4115 | Simile | National | | THISTOIL | | 2 |
| | | Account | | | | |
| | | Manager from | | | | Linkedin and Author of Only Solco |
| Matthew | Arnold | 2016-2019 | | Solco | P - 11.12.19 | stamped document |
| 1v1attiie W | Airioiu | 2010-2019 | | Syncores | 1 - 11.12.19 | samped document |
| | | | 1 | Shanghai | 1 | |
| Eric | Gu | Manager | | Syncores | P - 10.8.19 | |
| | | 1.14114501 | 1 | 2,1100100 | | |

| | 1 | | | Т | 1 | |
|-------------|------|-----------------------|---|----------------------|--------------|---|
| | | | | Shanhai | | |
| James (Jun) | Wen | President | | Syncores | P - 11.12.19 | Linkedin |
| Frank | Zhao | VP | | Shanghai Syncores | D 11 12 10 | Linkedin |
| FIANK | Zhao | VP | Prinhury I | BioPharm Ltd | P - 11.12.19 | Linkedin |
| | | General | 1 i i i i i i i i i i i i i i i i i i i | Joi nai in Etu | · | |
| Wenjian | Cai | Manager | | Prinbury | P - 11.12.19 | Prinbury website |
| | | Executive | | | | |
| | | Deputy | | | | |
| | | General | | | | |
| Dachuan | Zhao | Manager | | Prinbury | P - 11.12.19 | Prinbury website |
| | | Executive | | | | |
| Ping | Wen | Director | | Prinbury | P - 11.12.19 | Prinbury website |
| ** | 37' | | maceutical | D : 1 | B 11 12 10 | |
| Yuanyuan | Xie | Director Affa | | Prinbury | P - 11.12.19 | Prinbury website |
| т: | Tan | Proje | | D.: | D 11 12 10 | D |
| Li | ran | | agement | Prinbury | P - 11.12.19 | Prinbury website |
| | | Deputy General | | | | |
| | | Manager of | | | | |
| | | Analysis and | | | | |
| Wei | Tian | Research | | Prinbury | P - 11.12.19 | Prinbury website |
| | | Deputy | | , | | 3 |
| | | General | | | | |
| | | Manager of | | | | |
| | | Pharmaceutica | | | | |
| | | 1 Preparation | | | | |
| | 0.1 | Product | | | | |
| Hongchun | Qiu | Development | | Prinbury | P - 11.12.19 | Prinbury website |
| | | | | | | Prepared Method Verification |
| C1. i.e. | Chen | G. i. antint | | D.: | D 11 12 10 | Report for Valsartan PRINSTON00039715 |
| Shine | Chen | Scientist | | Prinbury | P - 11.12.19 | Reviewed Method Verification |
| | | Senior | | | | Report for Valsartan |
| Tina | Liu | Scientist | | Prinbury | P - 11.12.19 | PRINSTON00039715 |
| 11114 | Liu | Selentist | | Timoury | 1 11.12.17 | Approved Method Verification |
| | | Senior | | | | Report for Valsartan |
| Yun | Tian | Director | | Prinbury | P - 11.12.19 | PRINSTON00039715 |
| | | | | | | Approved Method Verification |
| | | | | | | Report for Valsartan |
| Lily | Tan | QA Manager | | Prinbury | P - 11.12.19 | PRINSTON00039715 |
| | | | | | | |
| | | | | | | Prepared Dissolution Comparison |
| | | | | | | Study Report of Valsartan |
| Alex | Liu | Scientist | | Prinbury | P - 11.12.19 | PRINSTON00050114 |
| | | | | | | Prepared Method Robustness Study |
| A 11 | т : | Associate | | D : 1 | D 11 12 10 | Report for Valsartan |
| Ashley | Lin | Scientist | | Prinbury | P - 11.12.19 | PRINSTON0039541 |
| | | E | | | | Reviewed and approved Master |
| Yula | Wor | Executive Director | | Drinburg | P - 11.12.19 | Production Batch Record Approval PRINSTON00064070 |
| ı ula | Wang | Director | | Prinbury sultants | F - 11.12.19 | 1 KINS I ON000040 / 0 |

Case 1:19-md-02875-RMB-SAK Document 312-7 Filed 12/05/19 Page 13 of 13 PageID: 4726

| | | | 1 | | |
|---------|------------|-------------|----------------|--------------|------------------------|
| | | | Alavanda | | |
| | | | Regulatory & | | |
| | | | Drug | | |
| | | | Development | | |
| | | | Consulting, | | |
| | | | Inc. | | |
| | | | (Regulatory | | |
| | | | Consultant for | | |
| | | | Prinston | | |
| | | | Pharmaceutica | | |
| Derek | Zhang, PhD | | l Inc.) | D - 10.23.19 | |
| | | | Jonn | | |
| | | | Laboratories | | |
| | | Chief | Inc. | | |
| | | Scientific | (Consultant | | |
| | | Officer & | for Prinston | | |
| | | Senior Vice | Pharmaceutica | | |
| Dylan | Yao, Ph.D. | President | l Inc.) | D - 10.23.19 | |
| | | | | | |
| | | | Consultant | | |
| | | VP of Drug | from InnoCare | | |
| | | Safety and | Pharma, Inc. | | |
| Charles | Wang | DMPK | for ZHP | D 10.23.19 | |
| Douglas | Campbell | Consultant | ZHP | P - 11.22.19 | Email PRINSTON00070408 |